In honor of May, Brain Tumor Awareness Month, Culicchia Neurological spoke with Aaron Mammoser, MD, the Kelsey Bradley Favrot Chair in Neuro-Oncology at LSU Health New Orleans School of Medicine’s Department of Neurosurgery about a new clinical trial for brain tumor patients that provides researchers with more flexibility to adjust enrollment based on previously enrolled patient’s response to treatment.
According to Dr. Mammoser, patients with a newly diagnosed glioblastoma or with a glioblastoma that has started to grow again after initial treatment may be eligible for the trial. The design of this trial offers patients an increased likelihood of receiving a treatment that will work for their tumor compared to other standard trial designs.
Patients can obtain more information about this trial, entitled “International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM” by visiting nolabraintumor.com or by calling (504)568-1611.
“This trial is studying multiple treatment options, with the results of molecular testing on the tumor determining which “arm” or subgroup of the trial that a person would qualify for,” Dr. Mammoser explained. “It’s designed to adaptively randomize people to treatment options based on information collected as the trial is carried out. This should allow for a higher likelihood that patients are assigned to an arm that will turn out to be effective for their tumor.”
The adaptive nature of the trial will hopefully streamline the drug development and approval process, Dr. Mammoser said.
